Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Immuno-oncology Therapy Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Immuno-oncology Therapy Industry
  • 1.7 COVID-19 Impact: Immuno-oncology Therapy Market Trends

    • 2 Global Immuno-oncology Therapy Quarterly Market Size Analysis

    • 2.1 Immuno-oncology Therapy Business Impact Assessment - COVID-19
      • 2.1.1 Global Immuno-oncology Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Immuno-oncology Therapy Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Immuno-oncology Therapy Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Immuno-oncology Therapy Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Immuno-oncology Therapy Market
    • 3.4 Key Players Immuno-oncology Therapy Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Immuno-oncology Therapy Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Monoclonal Antibodies
      • 1.4.2 Immune Checkpoint Inhibitors
      • 1.4.3 Immune System Modulators
      • 1.4.4 Cancer Vaccines
      • 1.4.5 Others
    • 4.2 By Type, Global Immuno-oncology Therapy Market Size, 2019-2021

    5 Impact of Covid-19 on Immuno-oncology Therapy Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Ambulatory Surgical Center
      • 5.5.3 Others
    • 5.2 By Application, Global Immuno-oncology Therapy Market Size, 2019-2021
      • 5.2.1 By Application, Global Immuno-oncology Therapy Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Amgen
      • 7.1.1 Amgen Business Overview
      • 7.1.2 Amgen Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.1.3 Amgen Immuno-oncology Therapy Product Introduction
      • 7.1.4 Amgen Response to COVID-19 and Related Developments
    • 7.2 AstraZeneca
      • 7.2.1 AstraZeneca Business Overview
      • 7.2.2 AstraZeneca Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.2.3 AstraZeneca Immuno-oncology Therapy Product Introduction
      • 7.2.4 AstraZeneca Response to COVID-19 and Related Developments
    • 7.3 Bristol-Myers Squibb
      • 7.3.1 Bristol-Myers Squibb Business Overview
      • 7.3.2 Bristol-Myers Squibb Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Product Introduction
      • 7.3.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.4 Eli-Lilly
      • 7.4.1 Eli-Lilly Business Overview
      • 7.4.2 Eli-Lilly Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.4.3 Eli-Lilly Immuno-oncology Therapy Product Introduction
      • 7.4.4 Eli-Lilly Response to COVID-19 and Related Developments
    • 7.5 Roche
      • 7.5.1 Roche Business Overview
      • 7.5.2 Roche Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.5.3 Roche Immuno-oncology Therapy Product Introduction
      • 7.5.4 Roche Response to COVID-19 and Related Developments
    • 7.6 GlaxoSmithKline
      • 7.6.1 GlaxoSmithKline Business Overview
      • 7.6.2 GlaxoSmithKline Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.6.3 GlaxoSmithKline Immuno-oncology Therapy Product Introduction
      • 7.6.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.7 Janssen Biotech
      • 7.7.1 Janssen Biotech Business Overview
      • 7.7.2 Janssen Biotech Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.7.3 Janssen Biotech Immuno-oncology Therapy Product Introduction
      • 7.7.4 Janssen Biotech Response to COVID-19 and Related Developments
    • 7.8 Merck
      • 7.8.1 Merck Business Overview
      • 7.8.2 Merck Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.8.3 Merck Immuno-oncology Therapy Product Introduction
      • 7.8.4 Merck Response to COVID-19 and Related Developments
    • 7.9 Novartis
      • 7.9.1 Novartis Business Overview
      • 7.9.2 Novartis Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.9.3 Novartis Immuno-oncology Therapy Product Introduction
      • 7.9.4 Novartis Response to COVID-19 and Related Developments
    • 7.10 Pfizer
      • 7.10.1 Pfizer Business Overview
      • 7.10.2 Pfizer Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.10.3 Pfizer Immuno-oncology Therapy Product Introduction
      • 7.10.4 Pfizer Response to COVID-19 and Related Developments
    • 7.11 Sanofi
      • 7.11.1 Sanofi Business Overview
      • 7.11.2 Sanofi Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.11.3 Sanofi Immuno-oncology Therapy Product Introduction
      • 7.11.4 Sanofi Response to COVID-19 and Related Developments
    • 7.12 Spectrum Pharmaceuticals
      • 7.12.1 Spectrum Pharmaceuticals Business Overview
      • 7.12.2 Spectrum Pharmaceuticals Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Product Introduction
      • 7.12.4 Spectrum Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.13 Takeda
      • 7.13.1 Takeda Business Overview
      • 7.13.2 Takeda Immuno-oncology Therapy Quarterly Revenue, 2020
      • 7.13.3 Takeda Immuno-oncology Therapy Product Introduction
      • 7.13.4 Takeda Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Immuno-oncology Therapy, including the following market information:
      Global Immuno-oncology Therapy Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immuno-oncology Therapy Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immuno-oncology Therapy Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immuno-oncology Therapy Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck, Novartis, Pfizer, Sanofi, Spectrum Pharmaceuticals, Takeda, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Monoclonal Antibodies
      Immune Checkpoint Inhibitors
      Immune System Modulators
      Cancer Vaccines
      Others

      Based on the Application:
      Hospitals
      Ambulatory Surgical Center
      Others

      Buy now